EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Anti‐Tumor Effect of Toosendanin and Paclitaxel on Triple‐Negative Breast Cancer via Regulating ADORA2A‐EMT Related Signaling

Juan Zhang, Hong-Xi Xu, Yu-Lin Wu, William Chi Shing Cho, Yan-Fang Xian iD, Zhi-Xiu Lin

Advanced Biology · 2023

DOI: 10.1002/adbi.202300062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Biology, 2023. Verfasst von Juan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Triple Negative Breast Neoplasms, Triterpenes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) is an aggressive cancer with very poor prognosis. Combination therapy has proven to be a promising strategy for enhancing TNBC treatment efficacy. Toosendanin (TSN), a plant‐derived triterpenoid, has shown pleiotropic effects against a variety of tumors. Herein, it is evaluated whether TSN can enhance the efficacy of paclitaxel (PTX), a common chemotherapeutic agent, against TNBC. It is found that TSN and PTX synergistically suppress the proliferation of TNBC cell lines such as MDA‐MB‐231 and BT‐549, and the combined treatment also inhibits the colony formation and induces cell apoptosis. Furthermore, this combination shows more marked migratory inhibition when compared to PTX alone. Mechanistic study shows that the ADORA2A pathway in TNBC is down‐regulated by the combination treatment via mediating epithelial‐to‐mesenchymal transition (EMT) process. In addition, the combined treatment of TSN and PTX significantly attenuates the tumor growth when compared to PTX monotherapy in a mouse model bearing 4T1 tumor. The results suggest that combination of TSN and PTX is superior to PTX alone, suggesting that it may be a promising alternative adjuvant chemotherapy strategy for patients with TNBC, especially those with metastatic TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalTriple Negative Breast NeoplasmsTriterpenesAnimalsHumansMiceCell Line, TumorPaclitaxelEpithelial-Mesenchymal TransitionReceptor, Adenosine A2A

Stichwörter der Autor:innen

apoptosiscell migrationpaclitaxeltoosendanintriple negative breast cancertumor growth

Substanzen

Drugs, Chinese HerbalPaclitaxelTriterpenestoosendaninADORA2A protein, humanReceptor, Adenosine A2A

Autor:innen und Institutionen

  • School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong SAR, China.
  • Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

ORCID-Profile: Yan-Fang Xian

Zitieren

APA

Zhang, J., Xu, H. X., Wu, Y. L., Cho, W. C. S., Xian, Y. F., & Lin, Z. X. (2023). Synergistic Anti‐Tumor Effect of Toosendanin and Paclitaxel on Triple‐Negative Breast Cancer via Regulating ADORA2A‐EMT Related Signaling. Advanced Biology. https://doi.org/10.1002/adbi.202300062

Vancouver

Zhang J, Xu HX, Wu YL, Cho WCS, Xian YF, Lin ZX. Synergistic Anti‐Tumor Effect of Toosendanin and Paclitaxel on Triple‐Negative Breast Cancer via Regulating ADORA2A‐EMT Related Signaling. Advanced Biology. 2023. doi:10.1002/adbi.202300062

BibTeX
@article{Zhang2023,
  author = {Zhang, Juan and Xu, Hong-Xi and Wu, Yu-Lin and Cho, William Chi Shing and Xian, Yan-Fang and Lin, Zhi-Xiu},
  title = {Synergistic Anti‐Tumor Effect of Toosendanin and Paclitaxel on Triple‐Negative Breast Cancer via Regulating ADORA2A‐EMT Related Signaling},
  journal = {Advanced Biology},
  year = {2023},
  doi = {10.1002/adbi.202300062}
}
Kostenlos starten →